# Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

> **NCT00233519** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Rochester** · enrollment: 17 (actual)

## Conditions studied

- Myotonic Dystrophy

## Interventions

- **DRUG:** SomatoKine/IPLEX

## Key facts

- **NCT ID:** NCT00233519
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2012-06-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00233519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00233519, "Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00233519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*